SEC 13F Intelligence

Managers / Q1 2025 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$124M
Q1 2025
Positions
27
Filings on Record
16
2019–present window
Filed
May 7, 2025
original filing

Summary

Bml Capital Management, LLC reported $124M in U.S.-listed holdings across 27 positions for Q1 2025.

Its largest position, AVIR, represents 18.4% of the portfolio.

Compared with Q4 2024, the fund opened 6 new positions and exited 4.

Portfolio Metrics

Turnover
+15.6%
vs prior filed quarter
Top-10 Concentration
+86.5%
share of reported value
Largest Position
+18.4%
Atea Pharmaceuticals
New / Exited
6 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 80.0%Other: 20.0%ADR: 0.0%
  • Common Stock · 80.0% · $99M
  • Other · 20.0% · $25M
  • ADR · 0.0% · $0

Quarter-over-Quarter Changes full breakdown →

vs Q4 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
THIRD HARMONIC BIO INCNEW+3.82M3.82M+$13M$13M
LAVA THERAPEUTICS NVNEW+1.96M1.96M+$2M$2M
ELEVATION ONCOLOGY INCNEW+5.89M5.89M+$2M$2M
SG7SAGE THERAPEUTICS INCNEW+135.1K135.1K+$1M$1M
TURNSTONE BIOLOGICS CORPNEW+1.10M1.10M+$452,388$452,388
ALMSALUMIS INCNEW+49.6K49.6K+$304,710$304,710
2KZ0KEZAR LIFE SCIENCES INCADDED+359.5K408.1K+$2M$2M
ISHARES TRSOLD OUT−260.0K0−$26M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2025

27 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1AVIRATEA PHARMACEUTICALS INChistory →COM18.41%$23M7.61M
2ACRSACLARIS THERAPEUTICS INChistory →COM17.65%$22M14.25M
3THIRD HARMONIC BIO INCCOM10.74%$13M3.82M
4AVU0ADVERUM BIOTECHNOLOGIES INChistory →COM NEW9.70%$12M2.74M
5ANTXAN2 THERAPEUTICS INChistory →COM6.33%$8M5.75M
6TILINSTIL BIO INChistory →COM NEW5.85%$7M416.7K
7EPIEURESSA PHARMA INChistory →COM NEW5.40%$7M4.22M
8ORMPORAMED PHARMACEUTICALS INChistory →COM NEW5.23%$6M3.02M
9IKENA ONCOLOGY INCCOM3.84%$5M3.71M
10PMVPPMV PHARMACEUTICALS INChistory →COM3.31%$4M3.75M
11WHWKWHITEHAWK THERAPEUTICS INChistory →COM2.72%$3M1.89M
12LAVA THERAPEUTICS NVSHS2.02%$2M1.96M
132KZ0KEZAR LIFE SCIENCES INChistory →COM NEW1.61%$2M408.1K
14ELEVATION ONCOLOGY INCCOM1.24%$2M5.89M
15ASTCASTROTECH CORPhistory →COM1.16%$1M220.4K
16CONNECT BIOPHARMA HLDGS LTDADS0.93%$1M2.09M
17SG7SAGE THERAPEUTICS INCCOM0.87%$1M135.1K
18ATHIRA PHARMA INCCOM0.74%$911,8703.20M
19MISTMILESTONE PHARMACEUTICALS INCOM0.74%$908,9861.14M
20LSTALISATA THERAPEUTICS INCCOM0.41%$509,605216.9K
21TURNSTONE BIOLOGICS CORPCOM0.37%$452,3881.10M
22VTGNVISTAGEN THERAPEUTICS INCCOM0.30%$375,000150.0K
23ALMSALUMIS INCCOM0.25%$304,71049.6K
24NXTCEURNEXTCURE INCCOM0.11%$131,379273.5K
25VERRICA PHARMACEUTICALS INCCOM0.06%$77,231174.7K
26HILLEVAX INCCOM0.02%$30,10220.8K
27698ACHILLES THERAPEUTICS PLCSPONSORED ADS0.00%$03.80M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.